Is LLY a good stock to buy?
Eli Lilly and Company · end-of-day data as of Nov 13, 2026
- ConsensusBuy · 32
- News
- Trendbullish
- MAs4 of 4
- MACD3.55
- Sector▲ +15.9%
- Earnings in82d
- P/E46.9x
- RSI70
- Support-15.1%
- Off 52w high-1.1%
- Volume0.6x
- Bollingerupper half
- FCF yield+1.4%
- 52w range$851–$1,460
- ATR+3.1%
- Off ATH-1.1%
- PT$1,403.73 -2.8%
- P/E vs own+19.1%
- P/E vs sector+45.4%
- Insiders-$14.65M
Updates with the 15-min delayed price. Not a forecast or investment advice.
Is Eli Lilly a good stock to buy?
Eli Lilly is strong on 5 of the 5 questions about the business. The price is low: 46.9 times its earnings, below its 3-year median of 58.4 (Nov 13, 2026). pretickt does not say whether to buy or sell.
- Demand growing
- Advantage hard to copy
- Economics very profitable
- Execution delivers
- Fragility sturdy
- Price below its usual
LLY sales growth revenue growth
+32%a year, for the last 3 yearsEli Lilly's sales grew 32% a year for 3 years, to $65.18B in fiscal 2025.
LLY analysts' forecast revenue estimates
+40%the sales they expect next fiscal year, on the lastAnalysts expect Eli Lilly's sales to grow 40% to $91.16B in fiscal 2026 (16 analysts).
LLY competitors
pretickt analysis+46%its sales in 12 months, on a year before
Eli Lilly's sales grew 46% in the 12 months to Sep 30, 2026, faster than AbbVie (+11%), Amgen (+8%) and Merck (+5%).
LLY customers' spending
pretickt analysis+23%what its customers invest, on a year before
Cencora, Cardinal Health and McKesson, customers of Eli Lilly, spent 23% more on capital in their latest quarter (to Sep 30, 2026) than a year before.
LLY sales by business revenue by segment
94%of its sales from ProductProduct brought Eli Lilly 94% of its sales in fiscal 2025; Collaboration and Other Revenue 6%.
LLY return on capital ROIC
pretickt analysis47%earned before tax on the money invested in itEli Lilly earned 47% before tax on the capital invested in it in the 12 months to Sep 30, 2026; AbbVie 36%, Amgen 25% and Merck 12%.
LLY margin on each sale gross margin
84%left after making the productEli Lilly kept 84% of each sale after making the product in the 12 months to Sep 30, 2026; its competitors' median is 76%.
LLY margin after costs profit margin
46%of sales left after running the businessEli Lilly's operating margin was 46% in the 12 months to Sep 30, 2026, against 30% in fiscal 2022.
LLY cash generated free cash flow
$19.66Bcash left after investing, last 12 monthsEli Lilly generated $19.66B of free cash flow in the 12 months to Sep 30, 2026, less than its reported profit.
LLY earnings vs estimates
8 of 8quarters above the analysts' estimateEli Lilly beat the analysts' profit estimate in each of its last 8 quarters, the latest on Oct 29, 2026.
LLY insider selling
-$1.21Bsold, net, by its executives in 12 monthsEli Lilly's executives and directors sold a net $1.21B of shares in the 12 months to Nov 13, 2026; none bought.
LLY number of employees
+6%more people in a yearEli Lilly had 50,000 employees at the end of fiscal 2025, 6% more than a year before.
LLY CEO pay
$36.7Mfor fiscal 2025, 64% of it in stock and optionsEli Lilly paid its CEO $36.7M for fiscal 2025, 64% of it in stock and options.
LLY financial health Altman Z-score
9.5Altman Z-score, safe above 3Eli Lilly's Altman Z-score is 9.5 (Nov 13, 2026), above 3, where the safe zone starts.
LLY quality checks Piotroski score
8 of 9checks passedEli Lilly passes 8 of the 9 Piotroski checks in the 12 months to Sep 30, 2026; it misses on the current ratio.
LLY biggest customers
60%of sales from its 3 biggest customersMcKesson, Cencora and Cardinal Health made 60% of Eli Lilly's sales in fiscal 2025.
LLY in past recessions
pretickt analysis+7%its sales in the worst oneEli Lilly's sales grew through each of the last 2 US recessions (2008–09 and 2020).
LLY price vs profit P/E ratio
46.9×a year's earningsEli Lilly's P/E ratio is 46.9 (Nov 13, 2026), below its 3-year median of 58.4.
LLY price vs competitors
pretickt analysis46.9×a year's earnings, against its competitors
Investors pay 46.9 times Eli Lilly's earnings (Nov 13, 2026), more than for Amgen (27.0), less than for Merck (152.3) and AbbVie (50.6).
LLY analysts' target price target
-3%to their average targetAnalysts' average price target for Eli Lilly is $1,404, 3% below the Nov 13, 2026 close of $1,443.50.
LLY growth priced in fair value
pretickt analysis+24%a year, for ten years, to be worth the priceAt $1,443.50 a share, Eli Lilly's free cash flow must grow about 24% a year for ten years to be worth the price (Nov 13, 2026).
What is Eli Lilly's P/E ratio?
Eli Lilly's P/E ratio is 46.9 (Nov 13, 2026), below its 3-year median of 58.4. Investors pay 46.9 times Eli Lilly's earnings (Nov 13, 2026), more than for Amgen (27.0), less than for Merck (152.3) and AbbVie (50.6).
Who are Eli Lilly's biggest competitors?
pretickt compares Eli Lilly with Johnson & Johnson, AbbVie, Merck and Amgen. Eli Lilly's sales grew 46% in the 12 months to Sep 30, 2026, faster than AbbVie (+11%), Amgen (+8%) and Merck (+5%).
Is Eli Lilly profitable?
Eli Lilly's operating margin was 46% in the 12 months to Sep 30, 2026, against 30% in fiscal 2022. Eli Lilly generated $19.66B of free cash flow in the 12 months to Sep 30, 2026, less than its reported profit.
Are insiders selling Eli Lilly stock?
Eli Lilly's executives and directors sold a net $1.21B of shares in the 12 months to Nov 13, 2026; none bought.
How does Eli Lilly make money?
Product brought Eli Lilly 94% of its sales in fiscal 2025; Collaboration and Other Revenue 6%.
Who owns Eli Lilly stock?
4,817 institutions hold 89% of Eli Lilly's shares (Jun 30, 2026); Vanguard and BlackRock added shares that quarter, Lilly Endowment sold some.
How many employees does Eli Lilly have?
Eli Lilly had 50,000 employees at the end of fiscal 2025, 6% more than a year before.
Who are Eli Lilly's biggest customers?
McKesson, Cencora and Cardinal Health made 60% of Eli Lilly's sales in fiscal 2025. Cencora, Cardinal Health and McKesson, customers of Eli Lilly, spent 23% more on capital in their latest quarter (to Sep 30, 2026) than a year before.
From the companies' statements (FMP), their filings read by pretickt, the analysts and the insiders, as of Nov 13, 2026. Each card says what a fact means for its question, never what to do with the stock: for information only, not investment advice.